A
1.55
-0.12 (-7.19%)
| Previous Close | 1.67 |
| Open | 1.69 |
| Volume | 291,584 |
| Avg. Volume (3M) | 863,288 |
| Market Cap | 154,988,528 |
| Price / Sales | 3.35 |
| Price / Book | 3.91 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 |
| Profit Margin | -139.74% |
| Operating Margin (TTM) | -1,216.52% |
| Diluted EPS (TTM) | -1.26 |
| Quarterly Revenue Growth (YOY) | -76.90% |
| Total Debt/Equity (MRQ) | 43.39% |
| Current Ratio (MRQ) | 3.34 |
| Operating Cash Flow (TTM) | -229.34 M |
| Levered Free Cash Flow (TTM) | -92.86 M |
| Return on Assets (TTM) | -17.22% |
| Return on Equity (TTM) | -90.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Alector, Inc. | Bearish | Bearish |
AIStockmoo Score
-0.9
| Analyst Consensus | -0.5 |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.90 |
|
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.61% |
| % Held by Institutions | 80.74% |
| 52 Weeks Range | ||
| Median | 3.50 (125.81%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Mizuho | 28 Jul 2025 | 3.50 (125.81%) | Buy | 1.76 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BERKLEY NEIL LINDSAY | - | 2.59 | -15,842 | -41,031 |
| KENKARE-MITRA SARA | - | 2.59 | -23,638 | -61,222 |
| ROSENTHAL ARNON | - | 2.59 | -51,562 | -133,546 |
| WONG-SARAD GRACE | - | 2.59 | -5,910 | -15,307 |
| Aggregate Net Quantity | -96,952 | |||
| Aggregate Net Value ($) | -251,106 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 2.59 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ROSENTHAL ARNON | Officer | 02 Sep 2025 | Sell (-) | 51,562 | 2.59 | 133,546 |
| KENKARE-MITRA SARA | Officer | 02 Sep 2025 | Sell (-) | 23,638 | 2.59 | 61,222 |
| BERKLEY NEIL LINDSAY | Officer | 02 Sep 2025 | Sell (-) | 15,842 | 2.59 | 41,031 |
| WONG-SARAD GRACE | Officer | 02 Sep 2025 | Sell (-) | 5,910 | 2.59 | 15,307 |
| Date | Type | Details |
|---|---|---|
| 28 Aug 2025 | Announcement | Alector to Participate in Upcoming Healthcare Conferences |
| 07 Aug 2025 | Announcement | Alector Reports Second Quarter 2025 Financial Results and Provides Business Update |
| 31 Jul 2025 | Announcement | Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call |
| 13 Jun 2025 | Announcement | Alector Provides Executive Leadership Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |